EU Recommends Second Covid Booster Jab for Over-60s
-AFP
https://twitter.com/AFP/status/1546422332973060096
Drugmakers, Health Authorities Discarding Several Million COVID-19 Vaccine Doses: Report
Wall Street Journal reported that governments, drugmakers, and vaccination sites are discarding several unused COVID-19 vaccine doses amid declining…
AstraZeneca’s COVID-19 Treatment Allowed In China’s Southern City: Reuters
AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 antibody cocktail has been cleared for use in a medical tourism zone in China’s southern…
AstraZeneca Shares Data At EASL And ESMO World GI For IMFINZI Combinations In Patients With Liver And Biliary Tract Cancers
survival vs. sorafenib in patients with unresectable liver cancer regardless of baseline liver functional reserve
TOPAZ-1 Phase III trial subgroup analysis showed the addition of IMFINZI to standard-of-care chemotherapy
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca’s COVID-19 Vaccine
Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents…
Oxford Biomedica Signed New Three year Agreement with AstraZeneca
Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that it has signed a new three year Master Services & Development Agreement ("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca") which would facilitate potential future manufacturing opportunities for the AstraZeneca COVID-19 vaccine.